medigraphic.com
Anales de la Sociedad Mexicana de Oftalmología y Archivos de la Asociación Para Evitar la Ceguera en México

2006, Number 5

<< Back Next >>

Rev Mex Oftalmol 2006; 80 (5)

Análisis de expresión de PCNA, p53 y bcl-2 en la secuencia melanosis adquirida primaria-melanoma conjuntival

Torres-Bernal LF, Díaz-Rubio JL, Sánchez P, Rodríguez-Reyes A, Valles-Valles DR, Benitez-Bribiesca L

Language: Spanish
References: 39
Page: 234-240
PDF size: 546.34 Kb.


ABSTRACT

Objectives: To analyze the protein expresion of PCNA, p53 and bcl-2 in the sequence primary acquired melanosis (PAM)-conjunctival melanoma (CM).
Methods: PCNA, p53, and bcl-2 protein expresion was studied by immunohistochemistry in four cases of PAM and five cases of CM. A quantitative analysis was done counting the number of positive cells, present in tissues of the different cases.
Results: We demonstrated a direct relationship between PCNA overexpression and the malignant potencial of conjunctival lesions with major overexpression of PCNA in conjunctival melanomas in contrast to PAM cases. The 60% of CM cases presented a positive p53 expression while all PAM, cases were negative. Finally we could not find an overexpression of bcl-2 in all cases.
Conclusion: p53 pathway participate importantly in the development of the sequence PAM -CM.


REFERENCES

  1. Shields CL. Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients. Trans Am Ophthalmol Soc 2000; 98:471-92.

  2. Seregard S. Conjunctival melanoma. Surv Ophthalmol 1998; 42(4):321-50.

  3. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100(1):57-70.

  4. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993; 9(4):138-41.

  5. Bartek J, Bartkova J, Vojtesek B, Staskova Z, Lukas J, Rejthar A y cols. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 1991; 6(9):1699-703.

  6. Lane DP. p53 guardian of the genome. Nature 1992; 358:15-16.

  7. Gannon JV, Greaves R, Iggo R, Lane DP. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 1990; 9(5): 1595-602.

  8. Mitselou A, Ioachim E, Kitsou E, Vougiouklakis T, Zagorianakou N y cols. Immunohistochemical study of apoptosisrelated Bcl-2 protein and its correlation with proliferation indices (Ki67, PCNA), tumor suppressor genes (p53, pRb), the oncogene c-erbB-2, sex steroid hormone receptors and other clinicopathological features, in normal, hyperplastic and neoplastic endometrium. In Vivo 2003; 17(5):469-77.

  9. Korsmeyer SJ. Bcl-2: an antidote to programmed cell death. Cancer Surv 1992; 15:105-118.

  10. Brantley MA Jr, Harbour JW. Deregulation of the Rb and p53 pathways in uveal melanoma. Am J Pathol 2000; 157:1795–1801.

  11. Kelman Z. PCNA structure, functions and interactions. Oncogene 1997; 14; 629–640.

  12. Ben-Izhak O, Bar-Chana M, Sussman L, Dobiner V, Sandbank J y cols. Ki67 antigen and PCNA proliferation markers predict survival in anorectal malignant melanoma. Histopathology 2002; 41(6):519-25.

  13. Loggini B, Rinaldi I, Pingitore R, Cristofani R, Castagna M, Barachini P. Immunohistochemical study of 49 cutaneous melanomas: p53, PCNA, Bcl-2 expression and multidrug resistance. Tumori 2001; 87(3):179-86.

  14. Mooy CM, Luyten GPM, De Jong PTVM, Luider TM, Stijnen T, Van de Ham F y cols. Immunohistochemical and prognostic analysis of apoptosis and proliferation in uveal melanoma. Am J Pathol 1995; 147:1.097-1.104.

  15. Rodriguez-Reyes AA, Rios y Valles-Valles D, Corredor-Casas S, Gomez-Leal A. Advanced conjunctival melanoma. Can J Ophthalmol 2004; 39(4):453-60.

  16. Niezabitowski A, Czajecki K, Rys J, Kruczak A, Gruchala A y cols. Prognostic evaluation of cutaneous malignant melanoma: a clinicopathologic and immunohistochemical study. J Surg Oncol 1999; 70(3):150-60.

  17. Iyengar B. Expression of proliferating cell nuclear antigen (PCNA): proliferative phase functions and malignant transformation of melanocytes. Melanoma Res 1994; 4(5):293-5.

  18. Bjornhagen V, Bonfoco E, Brahme EM, Lindholm J, Auer G. Morphometric, DNA, and proliferating cell nuclear antigen measurements in benign melanocytic lesions and cutaneous malignant melanoma. Am J Dermatopathol 1994; 16(6):615-23.

  19. Vecchiato A, Rossi CR, Montesco MC, Frizzera E, Seno A y cols. Proliferating cell nuclear antigen (PCNA) and recurrence in patients with cutaneous melanoma. Melanoma Res 1994; 4(4):207-11.

  20. Seregard S. Cell proliferation as a prognostic indicator in conjunctival malignant melanoma. Am J Ophthalmol 1993; 116(1):93-7.

  21. Seregard S. Cell growth and p53 expression in primary acquired melanosis and conjunctival melanoma. J Clin Pathol 1996; 49(4):338-42.

  22. Tobal K, Warren W, Cooper CS, McCartney A, Hungerford J, Lightman S. Increased expression and mutation of p53 in choroi- dal melanoma. Br J Cancer 1992; 66:900-904.

  23. Korabiowska M, Brinck U, Hoenig JF y cols. Significance of p53 antigen in malignant melanomas and naevi of the head and neck area. Anticancer Res 1995; 15:855-859.

  24. Jay M, McCartney ACE. Familial malignant melanoma of the uvea and p53; A Victorian detective story. Surv Ophthalmol 1993; 37:457-462.

  25. Janssen K, Kuntze J, Busse H, Schmid KW. p53 oncoprotein overexpression in choroidal melanoma. Mod Pathol 1996; 9:267-272.

  26. Stretch JR, Gatter KC, Ralfkiaer E, Lane DP, Harris AL. Expression of mutant p53 in melanoma. Cancer Res 1991; 51: 4976-5979.

  27. Volkenandt M, Schlegel U, Nanus DM, Albino AP. Mutational analysis of the human p53 gene in malignant melanoma. Pigment Cell Res 1991; 4:35-40.

  28. Sparrow LE, Soong R, Dawkins HJ, Iacopeta BJ, Heenan PJ. p53 gene mutation and expression in naevi and melanomas. Melanoma Res 1995; 5:93-100.

  29. Weis J, Heine M, Arden KC. Mutation and expression of TP53 in malignant melanomas. Recent Results Cancer Res 1995; 139:137-154.

  30. Rhim KJ, Hong SI, Hong WS, Lee SY, Lee DS, Jang JJ. Aberrant expression of p53 gene product in malignant melanoma. J Korean Med Sci 1994; 9:376-381.

  31. Barnhill RL, Castresana JS, Rubio MP y cols. p53 expression in cutaneous malignant melanoma: an immunohistochemical study of 87 cases of primary, recurrent, and metastatic melanoma. Mod Pathol 1994; 7:533-535.

  32. Van Den Oord JJ, Vandeghinste N, De Ley M, De Wolf-Peeters C. Bcl-2 expression in human melanocytes and melanocytic tumors. Am J Pathol 1994; 145:294-300.

  33. Plettenberg A, Ballum C, Pammer J, Mildner M, Strunk D, Weninger W y cols. Human melanocytes and melanoma cells constitutively express the Bcl-2 protooncogene in situ and in cell culture. Am J Pathol 1995; 146:651-659.

  34. Morales-Ducret CR, Van de Rijn M, Lebrun DP, Smoller Br. bcl-2 expression in primary malignancies of the skin. Arch Dermatol 1995; 131:909-912.

  35. Cerroni L, Soyer HP, Kerl H. bcl-2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi. Am J Dermatopathol 1995; 17:7-11.

  36. Ramsay JA, From L, Kahn HJ. bcl-2 protein expression in melanocytic neoplasms of the skin. Mod Pathol 1995; 8:150-154.

  37. Radhi JM. Malignant melanoma arising from nevi, p53, p16, and Bcl-2: expression in benign versus malignant components. J Cutan Med Surg 1999, 3:293–297

  38. Sulkowska M, Famulski W, Bakunowicz-Lazarczyk A, Chyczewski L, Sulkowski S. Bcl-2 expression in primary uveal melanoma. Tumori 2001; 87(1):54-7.

  39. Chana JS, Wilson GD, Cree IA, Alexander RA, Myatt N, y cols. c-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma. Br J Ophthalmol 1999; 83:110–114.




2020     |     www.medigraphic.com